Ipo News - Latest Updates & Headlines

Chhattisgarh's PRSU research for plant-based medicine to treat oral cancer

Raipur, March 6: A plant-based, effective, cost-efficient and zero side-effect medicine will soon be available in the market for the treatment of oral cancer as the professor and research scholar of Pt Ravishankar Shukla University (PRSU) in Chhattisgarh's capital Raipur are conducting extensive research in this direction.

J-K: Village in Bandipora hit by snow avalanche, no casualities reported

Bandipora, February 27: A snow avalanche occurred in the Khandyal village of Gurez valley in Jammu and Kashmir on Thursday afternoon. This affected many residential houses in the region. According to the officials, one house was damaged by the avalanche, but there was no immediate report of injuries or casualties.

LG Electronics bets big on India market ahead of its mega IPO

New Delhi, Feb 17: After Hyundai Motor India Ltd (HMIL), the Indian subsidiary of Hyundai Motor Company, listed on the Indian stock market in a landmark Rs 27,856 crore initial public offering (IPO), another South Korean giant LG's India arm is all set for its mega IPO.

AI to help SEBI process 1,000 IPOs in next 2 years: Madhabi Puri Buch

Mumbai, Jan 21: With the possibility of handling up to 1,000 initial public offerings (IPOs) in the next two years, the Securities and Exchange Board of India (SEBI) is adopting artificial intelligence (AI) to make the process of reviewing IPO documents in a faster and more efficient way, its Chairperson Madhabi Puri Buch said on Tuesday.

Malawi launches five year cholera control plan

Lilongwe, Jan 18: Malawi has launched a five-year cholera control plan, aiming to reduce the disease's annual incidence rate by 90 per cent and achieve a case fatality rate of less than 1 per cent by 2030.

ADSCC develops virus-free, clinical-grade induced pluripotent stem cells

Abu Dhabi, January 4: In a groundbreaking advancement toward cell therapy and regenerative medicine, the Abu Dhabi Stem Cells Center (ADSCC) has successfully developed clinical-grade induced pluripotent stem cells (iPSCs) that comply with the Good Manufacturing Practice protocols and are, as such, compliant with the strictest international standards for clinical applications.